M/s. Gericare Pharmaceuticals Pharmaceutical Import Profile — United States (DGFT 2022–2026)

Name: M/s. Gericare Pharmaceuticals Pharmaceutical Import Records from India — 3 Products, $844.1K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

M/s. Gericare Pharmaceuticals — Pharmaceutical Importer Profile (2026) | 3 Products, $844.1K Trade | TransData Nexus

M/s. Gericare Pharmaceuticals

Pharmaceutical Importer · United States · Vitamins & Supplements Focus · $844.1K Total Trade · DGFT Verified

M/s. Gericare Pharmaceuticals is a pharmaceutical importer based in United States with a total trade value of $844.1K across 3 products in 2 therapeutic categories. Based on 17 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. M/s. Gericare Pharmaceuticals sources from 1 verified Indian supplier, with Kausikh Therapeutics Private Limited accounting for 100.0% of imports.

M/s. Gericare Pharmaceuticals — Import Portfolio & Supplier Network

M/s. Gericare Pharmaceuticals import network — 3 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to M/s. Gericare Pharmaceuticals?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Kausikh Therapeutics Private Limited	$550.1K	13	100.0%

M/s. Gericare Pharmaceuticals sources from 1 verified Indian supplier across 3 distinct formulations. The sourcing is highly concentrated — Kausikh Therapeutics Private Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

Import Portfolio — Top 3 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Iron	Vitamins & Supplements	$350.0K	7	0.1%	5
2	Magnesium	Vitamins & Supplements	$300.0K	6	0.1%	9
3	Bisacodyl	Gastrointestinal	$194.1K	4	2.2%	7

M/s. Gericare Pharmaceuticals imports 3 pharmaceutical products across 2 categories into United States totaling $844.1K.

M/s. Gericare Pharmaceuticals — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

M/s. Gericare Pharmaceuticals is a pharmaceutical importer and buyer based in the United States, specializing in the procurement of finished pharmaceutical formulations from international suppliers. The company has established a focused portfolio, importing a total of $844,000 worth of products from India over 17 shipments between 2022 and 2026. This portfolio comprises three distinct products across two therapeutic categories, indicating a strategic approach to sourcing specific pharmaceutical formulations.

The company's primary supplier is Kausikh Therapeutics Private Limited, an Indian pharmaceutical manufacturer based in Gerugambakkam, Tamil Nadu. Established in 2000, Kausikh Therapeutics specializes in the manufacture of pharmaceutical formulations for the global market, adhering to stringent cGMP guidelines. Their product range includes analgesic and anti-inflammatory drugs, anti-convulsants, anti-depressants, anti-diabetic drugs, anti-fungal drugs, anti-hypertensive drugs, anti-ulcer drugs, antibiotic beta-lactams, antihistamines, and antihyperlipidemic drugs.

Gericare Pharmaceuticals' role in the U.S. pharmaceutical distribution network is that of an importer, focusing on sourcing specific finished pharmaceutical formulations from international manufacturers to meet domestic market demands.

2Distribution Network

While specific details about Gericare Pharmaceuticals' warehouse locations and logistics capabilities are not publicly available, the company's import activities suggest a distribution network that facilitates the receipt and distribution of pharmaceutical products within the United States. The 17 shipments from India over a four-year period indicate a structured logistics operation capable of managing international supply chains. The geographic coverage appears to be primarily domestic, serving various regions within the U.S.

3Industry Role

In the U.S. pharmaceutical supply chain, M/s. Gericare Pharmaceuticals functions as an importer, sourcing finished pharmaceutical formulations from international manufacturers, particularly from India. By focusing on specific therapeutic categories and products, Gericare Pharmaceuticals plays a pivotal role in diversifying the U.S. pharmaceutical market and ensuring the availability of specialized medications.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — M/s. Gericare Pharmaceuticals

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Gericare Pharmaceuticals demonstrates a high degree of supplier concentration, with all 17 shipments sourced exclusively from Kausikh Therapeutics Private Limited. This single-source dependency could pose risks related to supply chain disruptions, such as production delays or quality control issues. However, the consistent sourcing pattern over four years suggests a stable and reliable relationship between Gericare Pharmaceuticals and Kausikh Therapeutics. The absence of alternative suppliers may indicate strategic choices aimed at maintaining product consistency and quality.

2Supply Chain Resilience

The resilience of Gericare Pharmaceuticals' supply chain is closely tied to the stability and reliability of Kausikh Therapeutics Private Limited. Given that all imports originate from a single supplier, any disruptions at Kausikh Therapeutics could significantly impact Gericare Pharmaceuticals' operations. The lack of publicly available information on backup suppliers and formulation diversity suggests a potential vulnerability in the supply chain. Ensuring regulatory compliance, particularly adherence to cGMP guidelines by Kausikh Therapeutics, is crucial for maintaining the integrity and reliability of the supply chain.

Strategic Implications

Importing Pharmaceuticals into United States — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United States

1Regulatory Authority & Framework

In the United States, the Food and Drug Administration (FDA) is the primary regulatory authority overseeing the approval and regulation of pharmaceutical products. Key legislation governing pharmaceutical imports includes the Federal Food, Drug, and Cosmetic Act, which sets forth requirements for drug approval, labeling, and manufacturing practices. The FDA's Center for Drug Evaluation and Research (CDER) is responsible for evaluating new drugs and ensuring they meet safety and efficacy standards. For Indian generics to enter the U.S. market, they must undergo the Abbreviated New Drug Application (ANDA) process, demonstrating bioequivalence to the reference listed drug.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products entering the U.S. include obtaining an FDA registration for the establishment and listing of the drug products. Manufacturers must comply with Good Manufacturing Practice (GMP) regulations, which are recognized by the FDA. While the FDA does not have a formal recognition of WHO GMP or PIC/S certifications, compliance with these standards can facilitate the approval process. Wholesale distribution authorization is also required, ensuring that distributors meet specific regulatory standards for handling and distributing pharmaceutical products.

M/s. Gericare Pharmaceuticals — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Gericare Pharmaceuticals' focus on importing products in the Vitamins & Supplements and Gastrointestinal therapeutic categories suggests a strategic alignment with market demand for these segments. The substantial import value in these categories indicates a targeted approach to meet consumer needs in these areas. The specific selection of products like Iron, Magnesium, and Bisacodyl reflects an understanding of prevalent health concerns and treatment requirements within the U.S. market.

2Sourcing Profile

Gericare Pharmaceuticals' sourcing strategy emphasizes the procurement of generic drugs, particularly those that are well-established and widely used in the U.S. market. The focus on finished pharmaceutical formulations, rather than raw APIs or bulk drugs, indicates a preference for ready-to-market products that can be quickly distributed. India's robust pharmaceutical manufacturing capabilities and adherence to international quality standards make it a suitable partner for Gericare Pharmaceuticals' procurement needs.

3Market Positioning

Based on its product mix, Gericare Pharmaceuticals serves the retail pharmacy segment of the U.S. market. By importing widely used generic medications, the company ensures that these products are available to consumers through various retail channels, contributing to the accessibility and affordability of essential drugs.

Seller's Guide — How to Become a Supplier to M/s. Gericare Pharmaceuticals

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to partner with Gericare Pharmaceuticals, especially those offering products in the Vitamins & Supplements and Gastrointestinal categories. By aligning with Gericare Pharmaceuticals' existing product portfolio and quality standards, Indian exporters can expand their reach in the U.S. market. However, the single-source dependency on Kausikh Therapeutics highlights the importance of ensuring consistent product quality and reliable supply to establish a successful partnership.

2Requirements & Qualifications

Indian exporters seeking to supply M/s. Gericare Pharmaceuticals and enter the U.S. market must obtain FDA registration for their manufacturing facilities and drug products. Compliance with FDA's GMP regulations is mandatory, and adherence to WHO GMP or PIC/S standards can facilitate the approval process. Products must meet FDA's quality and labeling requirements, including batch testing, stability, and serialization mandates.

3How to Approach

Frequently Asked Questions — M/s. Gericare Pharmaceuticals

What products does M/s. Gericare Pharmaceuticals import from India?

M/s. Gericare Pharmaceuticals imports 3 pharmaceutical products across 2 categories. Top imports: Iron ($350.0K), Magnesium ($300.0K), Bisacodyl ($194.1K).

Who supplies pharmaceuticals to M/s. Gericare Pharmaceuticals from India?

M/s. Gericare Pharmaceuticals sources from 1 verified Indian suppliers. The primary supplier is Kausikh Therapeutics Private Limited (100.0% of imports, $550.1K).

What is M/s. Gericare Pharmaceuticals's total pharmaceutical import value?

M/s. Gericare Pharmaceuticals's total pharmaceutical import value from India is $844.1K, based on 17 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does M/s. Gericare Pharmaceuticals focus on?

M/s. Gericare Pharmaceuticals imports across 2 categories. The largest: Vitamins & Supplements (77.0%), Gastrointestinal (23.0%).

Get Full M/s. Gericare Pharmaceuticals Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.

Formulation	Value	Ships
Iron tabs(ferrous sulfate 325 MG	$269.2K	6
Magnesium oxide tabs 400 MG(232 x	$238.3K	6
Iron tabs (ferrous sulfate 325MG)	$42.6K	1